Regional cerebral perfusion was evaluated by SPECT with technetium 99m hexamethylpropyleneamine oxime (SSmTc HMPAO) as a tracer in 21 patients presenting with Parkinson's disease and in 11 normal controls. In the parkinsonian patients, scans were performed both off treatment, and after levodopa, and clinical dopaminergic responsiveness was evaluated. Uptake of HMPAO by the basal ganglia was significantly decreased in the parkinsonian subjects, compared with normal controls. This reduction was seen in both responders (n = 14) and non-responders (n = 7) to dopaminergic treatment. Uptake of HMPAO by the basal ganglia rose after treatment with levodopa, but the change was similar in both responders and non-responders. By contrast a striking difference in cortical HMPAO uptake was found between responders and non-responders, with significantly lower uptake in the medial temporal and posterior parietal cortex in the non-responders. This reduction was symmetrical. Basal ganglia perfusion assessed by this technique is unlikely to be of use in the diagnosis of Parkinson's disease that is responsive to dopaminergic treatment. The presence of extensive cortical involvement on a baseline scan correlates with a lack of dopaminergic responsiveness, however, and this may be useful diagnostically.
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The discovery that neuroprotective therapy may be effective in delaying the progression of early idiopathic Parkinson's disease' has reinforced the need for tests aiding early diagnosis. Whereas conventional structural imaging is usually normal, functional imaging shows abnormalities early in the disease. In the striatum reduced glucose metabolism and impaired uptake of ('8F)fluorodopa has been shown by positron emission tomography (PET).'3 With PET a decrease in basal ganglia blood flow has also been shown4; this is believed to result from the coupling of cerebral metabolism and blood flow, and to reflect lower metabolism in the affected basal ganglia. Although '8F-fluorodopa PET offers the most sensitive technique--for identifying early Parkinson's disease and differentiating it from other extrapyramidal syndromes,3 it is not available on a large enough scale to provide a routine method of diagnosis. SPECT is more widely available; use of the tracer technetium-99m hexamethylpropyleneamine oxime (99mTc HMPAO) allows semiquantitative imaging of regional cerebral blood flow.5 99mTc HMPAO is a lipophilic compound that easily crosses the blood brain barrier and is therefore taken up on first pass through the brain where it is retained for several hours.5 It is distributed in proportion to regional cerebral blood flow. Parkinson's disease on no treatment, were analysed qualitatively. Blinded to the diagnosis the cortical uptake was graded as normal (score 0), or showing mild (score 1), or severe (score 2) deficits.
Semiquantitative analysis Both pre and posttreatment scans were analysed. 99mTc HMPAO uptake in individual brain areas was quantified by placing square 4 x 4 pixel regions of interest, corresponding to 16x 16X 8 mm3 brain volumes, on positions standardised with reference to a stereotactic brain atlas."3 These consisted of the following numbers of regions of interest on each brain region: cerebellum nine, basal ganglia three, caudate one, putamen two, thalamus two, prefrontal region three, anterior frontal eight, posterior frontal three, anterior parietal three, posterior parietal three, superior parietal six, inferior parietal six, lateral temporal nine, medial temporal nine, occipital nine, all bilaterally, and brainstem one. All quantitative analysis was performed by one observer blinded to treatment state. Intraobserver reproducibility of this method of measuring regional uptake was assessed by repeating the counting procedure on two separate days for five scans (10 cerebral hemispheres). The mean count per pixel per brain region was calculated for each brain region on both left and right sides. Static HMPAO SPECT does not allow absolute quantification of regional cerebral blood flows. Semi quantitative analysis can be performed by comparing uptake in the area under investigation with uptake in an area unaffected by the disease process. The cerebellum is pathologically relatively spared in Parkinson's disease and therefore it is commonly usually used as the reference region in SPECT studies in Parkinson's disease.7 "4'5 We expressed HMPAO uptake for each region as the ratio of uptake in that region to that in the cerebellum. As there were no significiant differences between uptake in the left and right hemispheres, both sides were included together in comparisons. To 
VISUAL ANALYSIS
The mean grade of cortical deficits was greater in subjects with Parkinson's disease than in normal controls (2-14 v 1-61; Wilcoxon; p < 0 004). Within the Parkinson's disease group severe cortical perfusion deficits were more common in nonresponders (7/7) than in responders (3/14) (x2, p < 005). The mean grade of cortical deficit was higher in non-responders (3-0), than in responders (1 71; Wilcoxon p < 0 05), or than in normal subjects (1-61; Wilcoxon p < 0 03) disease responder group for most regions the ratio of regional cerebral blood flow to cerebellar regional blood flow was not significantly different from controls, with only three regions showing significant reductions: posterior parietal (by 6-76%; p < 0-001), superior parietal (6-31%; p < 0-005), and posterior frontal (3.61%; p < 0-02). By contrast, in the non-responders a significant decrease was seen in all cortical regions except occipital and inferior parietal cortex-namely, prefrontal cortex (7-02%; p < 0-004), anterior frontal cortex (7-1 1%; p < 0-002), posterior frontal cortex (6-72%; p < 0004), superior parietal cortex (8-38%; p < 0'002), anterior parietal cortex (5 90%; p < 0 009), posterior parietal cortex (10-76%; p < 0 0001), medial temporal cortex (8&88%; p < 0-0005), and lateral temporal cortex (6&49%; p < 0-003).
Regional cerebral blood flow was significantly lower in the non-responders than in the responders in the medial temporal cortex (7 45%; p < 0 002), posterior parietal cortex (4 30%; p < 0 04), and pre-frontal cortex (5 00%; p < 0 05) To determine whether this reduction was symmetrical or asymmetrical absolute asymmetry ratios between the hemispheres were calculated for each cortical area, and the mean difference for each area, for each group, was compared between groups. There was no difference between ratios for any region between controls, responders, and nonresponders.
It has been suggested that the cortical changes represent functional changes consequent on the loss of subcortical-cortical connections. If this is the case asymmetrical cortical involvement might be expected in patients with clinically asymmetrical disease.
To test this hypothesis in responders with asymmetrical Parkinson's disease (12 subjects), cortical regional blood flow in the hemisphere contralateral to the affected side was compared with that in the hemisphere ipsilateral to the deficit. Changes after treatment with levodopa Mean regional blood flow in the putamen (ratio to cerebellar blood flow) in the patients with Parkinson's disease, increased by 3 17% (p < 0-001) after treatment with levodopa. This increase was similar in both responders (3 03%; p < 0-007) and non-responders (3-46%; p < 0-077); the lack of significance in the non-responders was due to the smaller number in this group. No significant changes were seen in either the responders or nonresponders in the caudate, other subcortical regions, or in any cortical regions after treatment with levodopa.
Asymmetry in basal ganglia regional blood flow has been reported in Parkinson's disease, and it has been suggested that it is reduced by levodopa. In our patients with Parkinson's disease mean (SD) basal ganglia asymmetry was reduced after levodopa (from 4-87 (3 50) to 2-40 (1-52); p < 0-006); this reduction was seen in both responders and non-responders (4-75 (3-53) to 2-11 (1-30) and 5 09 (4-97) to 2-99 (1-86) respectively). A decrease in basal ganglia asymmetry after treatment with levodopa was seen in 11 of the 14 responders and in six of the seven non-responders.
Discussion
Our results show that in Parkinson's disease, even early in the course of the disease, HMPAO SPECT indicates a significant decrease in regional blood flow in the basal ganglia. This is consistent with previous PET studies. 4 An early HMPAO SPECT study failed to show any consistent alteration in blood flow in the basal ganglia in 16 parkinsonian patients.'7 The patients were on treatment with levodopa, however, and basal ganglia uptake was assessed only visually and hence bilateral and symmetrical reductions in uptake may have been underestimated. A study with semiquantitative analysis showed increased asymmetries in basal ganglia uptake in patients with Parkinson's disease, particularly those with advanced disease.'4 Mean blood flow in the basal ganglia was lower in patients with untreated Parkinson's disease than in controls but this difference did not reach significance.'4 These two studies used single headed gamma cameras.'417 With the three headed high resolution camera used in our study we found significantly reduced regional blood flow in the basal ganglia, but there was an overlap between subjects with Parkinson's disease and controls ( fig 1) ; therefore the specificity of this finding is not sufficient to provide useful diagnostic information.
Levodopa increases global cerebral blood flow,'8 but less is known about its effect on regional cerebral blood flow. PET studies have shown that it may increase blood flow in the basal ganglia to a greater extent than flow in other regions,8 and this finding is supported by an HMPAO SPECT study in a small group of subjects.7 This approach might provide useful -*diagnostic information. We looked at basal ganglia regional blood flow by comparing HMPAO uptake in the basal ganglia with that in the cerebellum. Our results showed a significant relative increase in blood flow in the basal ganglia, and more specifically in the putamen, after treatment with levodopa. The relative increase was similar in both responders and non-responders; therefore this change is likely to be non-specific and certainly does not correlate with dopaminergic responsiveness. We did not compare changes before and after levodopa with those in normal subjects in order to reduce radiation dose in these subjects, but PET studies suggest that normal controls also show a relative rise in basal ganglia blood flow after levodopa although it may be to a lesser extent than that seen in patients with Parkinson's disease.8 Our results suggest that this approach will not prove useful diagnostically.
A striking finding in our patients with Parkinson's disease was of areas of pronounced reduction in cortical blood flow and this was strikingly more common in nonresponders than in responders. This global fall could result from the functional effects of loss of diffuse cortical connections, such as those from the nucleus basalis of Meynert, '9 or from cortical pathology. The first explanation was suggested after the finding of reduced regional blood flow in the frontal cortex contralateral to the clinical deficit. 4 We were unable to show any difference, however, in any cortical region contralateral to the worst side in our patients with asymmetrical disease. This favours a direct pathological involvement of the cerebral cortex. Areas particularly affected were the prefrontal cortex, frontoparietal regions, and medial temporal cortex. A highly significant reduction in medial temporal blood flow was seen in nonresponders compared with responders. This pattern is similar to that seen in Alzheimer's disease,720 and in Parkinson's disease complicated by dementia,20 although in our study no subjects had clinical dementia. This suggests additional cortical pathology in these patients. All our patients with Parkinson's disease fulfilled clinical criteria for idiopathic Parkinson as shown by no increase in the asymmetry ratios between hemispheres, suggests that vascular processes leading to multi-infarct dementia and a parkinsonian syndrome does not account for the changes seen, Similarly the cortical changes do not represent those seen in other possible differential diagnoses such as corticobasal degeneration2324 or multiple system atrophy; in the last the cortex is spared. What remains striking, however, is that even in the earliest clinical stages (most of the subjects were studied at presentation) pronounced cortical abnormalities are present in the dopaminergic non-responders suggesting additional cortical involvement. Therefore, HMPAO SPECT scanning early in the course of the disease may give useful diagnostic and pathophysiological information in parkinsonian syndromes. It should be remembered that although the distribution of HMPAO is a good approximation to regional cerebral blood flow,5 and less isotope will be distributed to regions of low perfusion, retention in such areas will be greater, and therefore the patterns revealed on HMPAO SPECT represent maps of isotope uptake. Furthermore, HMPAO uptake is an active process and the uptake deficits we detected may reflect impaired intracellular retention of HMPAO as well as reduced regional cerebral blood flow.25 Nevertheless the cortical abnormalities we describe may allow identification at an early stage of patients who will respond poorly to treatment and possibly later develop an atypical disease. Prolonged clinical follow up and eventual neuropathological correlation is required to determine the clinical course and pathological cause of these cortical deficits.
